Year: 2023
Type: review
Abstract: Salivary gland cancers (SGCs) are rare, accounting for less than 5% of all malignancies of the head and neck region, and are morphologically heterogeneous. The diagnosis is mainly based on histology, with the complementary aid of molecular profiling, which is helpful in recognizing some poorly differentiated, borderline, or atypical lesions. Instrumental imaging defines the diagnosis, representing a remarkable tool in the treatment plan. Ultrasound and magnetic resonance are the most common procedures used to describe the primary tumour. The treatment of SGCs is multimodal and consists of surgery, radiotherapy, and systemic therapy; each treatment plan is, however, featured on the patient and disease's characteristics. On 24 June 2022, in the meeting "Current management and future challenges in salivary gland cancers" many experts in this field discussed the state of the art of SGCs research, the future challenges and developments. After the meeting, the same pool of experts maintained close contact to keep these data further updated in the conference proceedings presented here. This review collects the insights and suggestions that emerged from the discussion during and after the meeting per se.
Source: Frontiers in Oncology
Authors: Laura D. Locati, Renata Ferrarotto, Lisa Licitra, Marco Benazzo, Lorenzo Preda, Davide Farina, Gemma Gatta, Davide Lombardi, Piero Nicolai, Vincent Vander Poorten, Melvin Lee Kiang Chua, Barbara Vischioni, Giuseppe Sanguineti, Patrizia Morbini, Isabel Fonseca, Davide Sozzi, Anna Merlotti, Ester Orlandi
Institutions: University of Pavia, Istituti Clinici Scientifici Maugeri, The University of Texas MD Anderson Cancer Center, University of Milan, Policlinico San Matteo Fondazione, Istituti di Ricovero e Cura a Carattere Scientifico, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, University of Padua, Universitair Ziekenhuis Leuven, KU Leuven, National Cancer Centre Singapore, National Center for Oncological Hadrontherapy, Instituto Nazionale Tumori Regina Elena, University of Lisbon, Instituto Português de Oncologia Francisco Gentil, University of Milano-Bicocca, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,295
OpenAlex ID: W4386894182